Adding Value: Sanofi, Google Partner On Diabetes Management
This article was originally published in Scrip
Sanofi and Google's unnamed life science company entered into a partnership to help diabetes patients and their doctors monitor their disease and remain compliant with dosing schedules for glucose-lowering medications via technology that has yet to be defined, but will amount to more than yet another easily ignored smartphone application.
You may also be interested in...
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.
Aspen Neuroscience, Pandion and iTeos raised $70m, $80m and $125m, respectively. Also, Glide Healthcare closed a €416m ($450m) fund; ElevateBio, Kallyope and SutroVax reveal VC mega-rounds; and Dragonfly adds new funding to its partnering proceeds.